Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
03/2005
03/10/2005WO2005021040A2 Compositions useful for treating gastrointestinal motility disorders
03/10/2005WO2005021039A1 Combination of cicletanine and an oral antidiabetic and/or blood lipid-lowering agent for treating diabetes and metabolic syndrome
03/10/2005WO2005021038A2 Agent for treating metabolic syndrome
03/10/2005WO2005021037A1 Composition comprising a pulmonary surfactant and a pde2 inhibitor
03/10/2005WO2005021004A1 Method for preventing or treating an optic neuropathy
03/10/2005WO2005021003A2 Immunosuppressive effects of pteridine derivatives
03/10/2005WO2005020989A1 Cancer treatment with epothilones
03/10/2005WO2005020983A2 Combination therapy for glycaemic control
03/10/2005WO2005020972A2 Combination therapy for the treatment of ocular neovascular disorders
03/10/2005WO2005020971A1 Use of an angiotensin ii antagonist for the prevention of myocardial infarction
03/10/2005WO2005020962A1 Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
03/10/2005WO2005020923A2 Composition and method for the treatment of cancer and other physiologic conditions based on modulation of the ppar-gamma pathway and her-kinase axis
03/10/2005WO2005020908A2 Selective inhibitors of stat-3 activation and uses thereof
03/10/2005WO2005020903A2 Methods of improving the safety of zonisamide therapy
03/10/2005WO2005020901A2 Delivery of a therapeutic agent in a formulation for reduced toxicity
03/10/2005WO2005020900A2 Delivery of a therapeutic agent in a formulation for reduced toxicity
03/10/2005WO2005020897A2 Compositions and methods for the treatment of disease associated with trp-p8 expression
03/10/2005WO2005020882A2 Compound capable of binding s1p receptor and pharmaceutical use thereof
03/10/2005WO2005020879A2 Compositions for treating pathologies that necessitate suppression of gastric acid secretion
03/10/2005WO2005011572A3 Combination of drugs for the treatment of neoplasms
03/10/2005WO2005007241A8 Parasiticidal composition
03/10/2005WO2005000355A8 Treatment of tumor by cotransferring chemotherapeutic agent with cytokine gene
03/10/2005WO2005000284A3 Diaryl ureas for diseases mediated by pdgfr
03/10/2005WO2004108062A3 Prophylaxis and/or treatment of portal hypertension
03/10/2005WO2004105731A8 Nasal formulations including a topical decongestant and a topical corticosteroid and their use in treatment of obstructive sleep apnea
03/10/2005WO2004100826A3 Dietary supplement and method for the treatment and prevention of digestive tract ulcers in equines and other animals
03/10/2005WO2004089415A3 COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST
03/10/2005WO2004087105A8 Combination formulations of platinum agents and fluoropyrimidines
03/10/2005WO2004056971A3 Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
03/10/2005WO2004034968A3 Combination therapy for controlling appetites
03/10/2005WO2003093409A3 Promoters exhibiting endothelial cell specificity and methods of using same
03/10/2005WO2003092720A8 A combination product comprising an anti-coagulant and anti-arrhythmic oxabispidenes
03/10/2005WO2003079987A3 A non-selective cation channel in neural cells and methods for treating brain swelling
03/10/2005WO2003073990A3 Treatment for asthma or allergies
03/10/2005WO2003073062A3 Reagents and methods for identifying and modulating expression of genes regulated by cdk inhibitors
03/10/2005WO2003037167A9 Pathway of rantes-mediated chemokine synthesis in astrocytes and methods of use therefor
03/10/2005WO2003010290A3 Novel class ii cytokine receptors and uses thereof
03/10/2005WO2001066772A9 Heparinase iii and uses thereof
03/10/2005US20050054734 obesity, hypotensive agents, pretreatment for diabetes, metabolism syndrome ; administering dopaminergic agents and agents which reduces noradrenergic activity
03/10/2005US20050054731 Includes a biguanide hypoglycemic agent, a lipid lowering agent, a blood pressure lowering agent and, preferably, an anti-platelet agent
03/10/2005US20050054727 For treating or delaying progression or onset of obesity, hypercholesterolemia, atherosclerosis, depression, osteoporosis, hypothyroidism, non-toxic goiter, reduced bone mass, density or growth, eating disorders, cardiac arrhythmia
03/10/2005US20050054726 Vaccine
03/10/2005US20050054723 Administration to the individual of a prostaglandin analogue selective for the EP2 prostanoid receptor in combination with an alpha-adrenergic agonist
03/10/2005US20050054719 Dimeric compounds and their use as anti-viral agents
03/10/2005US20050054718 4S, 5R, 6R)-5-Acetylamino-4-azido-6-[(S)-4-nitrophenoxycarbonyloxy)-(2-oxo-[1,3]dioxolan-4R-yl)methyl]- 5,6-dihydro-4H-pyran2-carboxylic acid methylester; modified at the carboxyl or hydroxyl or amino functions; orthomyxovirus and paramyxovirus infections; a long lung residency time and high potency
03/10/2005US20050054717 Coumarin derivative
03/10/2005US20050054708 Combinations of drugs for the treatment of neoplasms
03/10/2005US20050054696 Indole compounds and medicinal use thereof
03/10/2005US20050054685 Pharmaceutical composition
03/10/2005US20050054682 Pharmaceutical compositions comprising substituted benzimidazoles and methods of using same
03/10/2005US20050054673 Combination of phenylcarboxylic acid amides with beta-adrenoreceptor blockers and their use for the treatment of atrial arrhythmias
03/10/2005US20050054668 Antagonists of MCP-1 function and methods of use thereof
03/10/2005US20050054665 Adjust gene expresion; induction of immunology response; leukemia; antcancer agents; vaccines
03/10/2005US20050054663 GSK-3 inhibitors
03/10/2005US20050054656 Therapy for obesity, eating disorders, psychological disorders, antidepressants, central nervous system disorders
03/10/2005US20050054652 Methods of treating metabolic syndrome using dopamine receptor agonists
03/10/2005US20050054651 Compositions and methods for the treatment of disease associated with Trp-p8 expression
03/10/2005US20050054650 Suppression tumor growth
03/10/2005US20050054623 Transdermal supplying testosterone gel
03/10/2005US20050054619 Suppression tumor growth
03/10/2005US20050054618 Hypotensive agents; antiischemic agents; antiarrhythmia agents
03/10/2005US20050054617 Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis
03/10/2005US20050054602 Oligonucleotides containing activated lymphocytes; antibody therapy; antiallergens; skin disorders
03/10/2005US20050054594 Methods for particle-assisted polynucleotide immunization using a pulsed electric field
03/10/2005US20050054592 Alzheimer's disease; Parkinson's disease; isolated nucleic acids
03/10/2005US20050054587 Novel therapeutic indication of azithromycin for treatment of non-infective inflamatory diseases
03/10/2005US20050054585 Using saccharide; bone disorders
03/10/2005US20050054584 Reducing weight and damage cuased by diabetes; antidiabetic agents
03/10/2005US20050054577 Irritable bowel disorders; controlling permeability of intestine tissue ; anticholinergic agent
03/10/2005US20050054108 Yeast membrane protein expression system and its application in drug screening
03/10/2005US20050054095 For treatment and/or prevention of inflammation and autoimmune disease; vaccines
03/10/2005US20050054074 Cell line comprising embryonated poultry cells and attenuated viral particles for use as tool in generation of vaccine for treatment and prevention of in fection by of influenza virus; immunotherapeutics
03/10/2005US20050054041 Kini-3 motor protein and methods for its use
03/10/2005US20050054036 Growth factor isoform
03/10/2005US20050054018 Using cell cycle checkpoint activation modulators to prevent and treat cell proliferative disorders
03/10/2005US20050053935 Methods for diagnosing and treating diseases and conditions of the heart or digestive system, and cancer
03/10/2005US20050053678 Methods and compositions for betel nut chewing gum
03/10/2005US20050053676 Powdered composition for use as laxative
03/10/2005US20050053674 Pharmaceutical composition and method for retardation of the progression of atherosclerosis
03/10/2005US20050053673 Nutraceutical formulation for healing human bone due to accidental fracture or surgical replacement or grafting, containing lysine, proline, ascorbic acid, copper, and vitamin B6
03/10/2005US20050053670 use of an organic lubricant and no alkali metal salts of metaphosphates in an effective amount into the birth canal of the woman during delivery
03/10/2005US20050053664 Reduced toxicity; enhance efficiency; side effect reduction; anticarcinogenic agent; administering to a cancer patient admixture having (((1,4)-linked beta -D-mannopyranose)17-((1,6)-linked- beta -D-galactopyranose)10)12) and a chemotherapeutic agent
03/10/2005US20050053659 Methods and compositions for reducing the risk associated with the administration of opioid analgesics in patients with diagnosed or undiagnosed respiratory illness
03/10/2005US20050053619 Nose sprays for relief of congestion and pain using vegetable oils, menthol, benzoin, thymol and sodium bicarbonate in water
03/10/2005US20050053606 MUC1 extracellular domain and cancer treatment compositions and methods derived therefrom
03/10/2005US20050053599 Antagonist for endothelial growth agents for treatment of edema and for kidney dialysis
03/10/2005US20050053597 Composition and method for treatment of wounds
03/10/2005US20050053595 White cream bacteriostats, fungicide as vehicle for drug; receptivity
03/10/2005US20050053583 Method of inhibiting prion protein
03/10/2005US20050053572 Does not cause any side effects and has superior hair growth-promoting effects
03/10/2005US20050053560 Use of a composition containing extracts of Vitis vinifera and lycopersicum for protecting the skin
03/10/2005US20050053558 Lemon balm, passion flower, and valerian; and the hormone melatonin
03/10/2005US20050053555 Appetite control compositions and methods of use
03/10/2005US20050053553 Combined doses of formoterol and fluticasone
03/10/2005US20050051922 Dosage form comprising: controlled release core of an antihyperglycemic drug and an excipient.seal coat applied to the controlled release core; may also include immediate release thiazolidinedione coating over the seal coat
03/10/2005US20050051483 forskolin, isoforskolin or 7-deacetylforskolin complexing/solubilizing with cyclodextrin agent; ophthamology
03/10/2005CA2824106A1 Compound capable of binding s1p receptor and pharmaceutical use thereof
03/10/2005CA2537182A1 Compositions useful for treating gastrointestinal motility disorders
03/10/2005CA2537180A1 Cicletanine in combination with oral antidiabetic and/or blood lipid-lowering agents as a combination therapy for diabetes and metabolic syndrome
03/10/2005CA2537093A1 Compound capable of binding s1p receptor and pharmaceutical use thereof
1 ... 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 ... 1151